siRNA Septicemia Treatment Patent
Summary
USPTO granted Patent US12590304B2 to Suzhou Ribo Life Science Co., Ltd. covering an siRNA therapeutic targeting the kininogen (KNG) gene for treating septicemia. The patent includes 8 claims for the nucleic acid composition, pharmaceutical formulation, and siRNA conjugate. This is a standard patent grant公告 with no regulatory compliance obligations.
What changed
USPTO granted Patent US12590304B2 to Suzhou Ribo Life Science Co., Ltd. for an siRNA composition inhibiting kininogen (KNG) gene expression for septicemia treatment and prevention. The patent covers the sense strand (nucleotide sequence with ≤3 differences from SEQ ID NO: 1) and antisense strand (nucleotide sequence with ≤3 differences from SEQ ID NO: 2), along with pharmaceutical compositions and siRNA conjugates.
This is a routine patent grant with no compliance deadlines or required actions for external parties. Pharmaceutical and biotechnology companies developing siRNA-based sepsis therapeutics should note this existing patent portfolio when designing research programs to avoid potential infringement. The filing date was May 21, 2020, with Application No. 17595621.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
Grant US12590304B2 Kind: B2 Mar 31, 2026
Assignee
SUZHOU RIBO LIFE SCIENCE CO., LTD.
Inventors
Hongyan Zhang, Shan Gao, Daiwu Kang
Abstract
An siRNA which inhibits kininogen (KNG) gene expression, a pharmaceutical composition containing the siRNA, and an siRNA conjugate. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The siRNA contains a sense strand and an antisense strand. The sense strand contains nucleotide sequence I, nucleotide sequence I having the same length as the nucleotide sequence shown in SEQ ID NO: 1, with no more than three nucleotide differences. The antisense strand contains nucleotide sequence II, nucleotide sequence II having the same length as the nucleotide sequence shown in SEQ ID NO: 2, with no more than three nucleotide differences. The siRNA, the pharmaceutical composition thereof and the siRNA conjugate can effectively treat and/or prevent septicemia.
CPC Classifications
C12N 15/113 C12N 2310/14 C12N 2310/315 C12N 2310/322 C12N 2310/351 C12N 2320/11 C12N 2330/30 C12N 2310/343 C12N 2310/346 C12N 2310/3517 C12N 2320/32 A61K 47/549 A61K 31/713 A61K 47/54 A61P 31/04 A61P 21/00 A61P 21/04 A61P 37/00 C07H 21/02
Filing Date
2020-05-21
Application No.
17595621
Claims
8
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.